
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte Inc. is positioned favorably within the market for next-generation pneumococcal vaccines, evidenced by its VAX-24 and VAX-31 candidates demonstrating superior immune response in adult trials compared to existing products like Prevnar 20. The company's strong clinical performance, especially in infant populations with robust seroresponse rates, suggests a significant potential for sustained market leadership and expansion. With an estimated global revenue opportunity of $7-10 billion, Vaxcyte represents a compelling mid- to long-term investment in the biotech sector.
Bears say
Vaxcyte Inc. faces significant downside risks primarily stemming from potential delays in research and development processes as well as uncertainties regarding the efficacy and safety of its vaccine candidates, which could lead to disappointing clinical trial outcomes. The company is also susceptible to lower-than-anticipated commercial uptake and the possibility that competitor programs may progress more rapidly, adversely affecting its market position. Additionally, broader concerns related to anti-vaccine sentiment contribute to a negative sentiment surrounding Vaxcyte's stock, as reflected in the substantial decline in share value since late 2024.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares